ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Below Fifty Day Moving Average – Time to Sell?
by Amy Steele · The Cerbat GemProQR Therapeutics N.V. (NASDAQ:PRQR – Get Free Report) shares passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.20 and traded as low as $2.05. ProQR Therapeutics shares last traded at $2.16, with a volume of 737,755 shares changing hands.
Analysts Set New Price Targets
PRQR has been the subject of a number of research analyst reports. Chardan Capital reiterated a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research report on Tuesday, November 4th. Zacks Research raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.14.
View Our Latest Stock Analysis on ProQR Therapeutics
ProQR Therapeutics Trading Up 3.8%
The firm has a market capitalization of $227.25 million, a price-to-earnings ratio of -4.60 and a beta of 0.19. The firm’s 50-day moving average is $2.20 and its 200 day moving average is $2.24.
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The business had revenue of $3.38 million for the quarter, compared to the consensus estimate of $7.05 million. ProQR Therapeutics had a negative net margin of 273.20% and a negative return on equity of 58.70%. Analysts predict that ProQR Therapeutics N.V. will post -0.31 EPS for the current year.
Institutional Investors Weigh In On ProQR Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Osaic Holdings Inc. raised its position in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 4,500 shares during the last quarter. Fifth Third Bancorp acquired a new stake in ProQR Therapeutics during the 3rd quarter valued at approximately $64,000. Vontobel Holding Ltd. raised its holdings in ProQR Therapeutics by 76.5% during the 2nd quarter. Vontobel Holding Ltd. now owns 63,979 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 27,722 shares during the last quarter. OneDigital Investment Advisors LLC lifted its position in shares of ProQR Therapeutics by 23.1% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 80,000 shares of the biopharmaceutical company’s stock worth $170,000 after purchasing an additional 15,000 shares during the period. Finally, Jane Street Group LLC lifted its position in shares of ProQR Therapeutics by 699.3% in the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 79,720 shares during the period. Institutional investors and hedge funds own 32.65% of the company’s stock.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.
Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.